Combining benefits in glaucoma


Combining benefits in glaucoma

Attacking glaucoma with a combination treatment strategy achieves a significant reduction in intraocular pressure in patients unresponsive to monotherapy, according to a study presented at the annual meeting of ARVO in Florida.

Preliminary results of the EXACCT study [Evaluation of Xalatan (latanoprost) and Cosopt (dorzolamide hydrochloride/timolol maleate)] demonstrated IOP control in 92.6% of those patients who were unresponsive to, or were uncontrolled, with latanoprost, when treated with the combination treatment, Cosopt alone, or when the investigational agent was added to latanoprost therapy.

The multicentre, open-label, 12-week EXACCT study enrolled 343 patients across Canada. The preliminary study results related to 243 participants; 196 of the patients had either open-angle glaucoma or ocular hypertension and received Cosopt in addition to latanoprost after a four-week course of latanoprost monotherapy failed to control IOP. The remaining 47 patents were completely unresponsive to latanoprost and hence were switched to Cosopt therapy.

Mark Lesk, MD, EXACCT study co-author and vision health researcher with the Guy-Bernier Research Centre at Montreal's Maisonneuve-Rosemont Hospital, University of Montreal, Canada, noted a 28.3% (15.78 mmHg vs. 22.34 mmHg) reduction of IOP from latanoprost baseline, when patients received both latanoprost and Cosopt. In latanoprost unresponsive patients, Cosopt alone achieved an average reduction of 24.4% in IOP (17.29 mmHg vs. 23.14 mmHg). According to Lesk, the overall treatment strategy was generally well tolerated with the majority (77%) of adverse events being mild in nature.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.